Clinical Significance Of Serum TK1 Levels For Patients With Non-small-cell Lung Cancer When Undergoing Chemotherapy

Background: Malignant tumor is a serious threat to human life and health.Lung cancer being the most common incident cancer and the leading cause of cancer death in China and all over the world.Meanwhile lung cancer is the second leading cause of female malignant tumor death.About 1.38 million people died of lung cancer around the world each year.Therefore lung cancer is listed as the most harmful disease to human beings in the 21 st century by WHO.Mostly it is too late to treat lung cancer by surgical operation when it is diagnosed.In recent years,though,the more advanced treatment was found,but the is given priority to with chemotherapy treatment is still the main method of clinical treatment of patients with non-small cancer lung cancer.Lung cancer is also known as primary bronchial lung cancer which is the most commom originated in the bronchial mucosa or gland maligant tumor.Though the pathogeny of lung cancer is not yet clear,but it is known that environmental pollution and smoking are very important risk factors of lung cancer.Its morbidity and mortality showed an increasing trend in recent years.Early diagnosis and treatment has been very important to improve the curative effect and the quality of life of patients with lung cancer.The tumor markers earlier than imaging can reflect the existence of tumor progression or recurrence of the situation,so-called tumor markers mainly refers to certain substances produced by the tumor tissue or tumor markers and tumor-host interactions can exist,can be detected from the human body to the blood or other body fluids.Thymidine kinase(thymidine kinase,TK)is the key enzyme in remedial approach for human DNA synthesis which is also called metabolism of pyrimidine ring.TK1 converts deoxythymidine(d Td R)to deoxythymidinemonophosphate(d TMP),which eventually participate in DNA replication and synthesis.TK exists in two forms: TK1(cytoplasmic)and TK2(mitochondrial).TK2 participates in a separate cell cycle which has nothing to do with the cell cycle.The expression of TK1 which is usually called the cell cycle dependent marker is closely associated with cell cycle.TK1 activity increases in late G1 and peaks in the S phase and thendecreases during the M phase due to the action of aspecific degradation pathway.TK1 can be a good response to the proliferation of tumor cells,so TK1 is known as one of the great potential tumor markers.STK1 can be detected in certain cases such as anemia,infections,immune,system disease and so on.TK1 is in a low level or undetectable in resting stage cells and healthy human body but is higher in fetal tissue or proliferation cell in adult.The level of TK1 in proliferation cell can reach 2-100 times as much as its in normal people.At present,a large number of domestic and foreign research shows that TK1 is a valuable tumor marker.Monitoring the level of TK1 can be used for tumor screening,early diagnosis,curative effect evaluation and survival prediction.This paper discusses the significance of serum thymidine kinase 1 in the treatment of non-small-cell lung cancer patients with chemotherapy.Objective: To investigate the dynamic change and its clinical significance of serum TK1 in patients with NSCLC when undergoing 4 cycles of chemotherapy.Methods: In our study,we detected serum TK1 levels of 59 patients with NSCLC throughout 4 cycles of chemotherapy using Enhanced Chemiluminescence Western Blot and analyze its relationship with chemotherapy responses.Results:Serum TK1 levels with different chemotherapy regimens have no significant difference.Compared with before treatment,the serum TK1 levels in patients who had effective response were significantly lower than those detected after 4 cycles of chemotherapy.The serum TK1 levels in patients who had effective response were significantly lower than those in non-responders throughout 4 cycles of chemotherapy.The positive rates of serum TK1 in those who had effective response were lower than those in non-responders after the last two cycles of chemotherapy.Serum TK1 levels between lung squamous carcinoma and lung adenocarcinoma have no significant difference.Conclusion: The detection of the changes of serum TK1 in patients with NSCLC when undergoing chemotherapy is useful in evaluating the effect of chemotherapy and the later therapeutic schedule.